07:00 , Mar 18, 2013 |  BioCentury  |  Strategy

Japan's biggest biotech

Japanese pharmaceutical companies have historically been thought of as stodgy, insular and opaque, but that is changing fast. One year into the job, Kyowa Hakko Kirin Co. Ltd. 's CEO is building his company along...
08:00 , Nov 5, 2012 |  BioCentury  |  Finance

Asia-Pac expansion

Asia-Pac expansion Australian VC Octa Phillip Bioscience Managers will cast a wider net with its new fund, looking to both spend money and attract investors in the broader Asia Pacific. Last week, the firm's Asia...
07:00 , Jun 4, 2012 |  BC Week In Review  |  Company News

CK Life Sciences management update

CK Life Sciences International Inc. (HKSE:0775), Hong Kong, China   Business: Cancer, Nutraceuticals   Hired: John Chiplin as CEO, a newly created position, of CK's Polynoma LLC subsidiary, formerly CEO of Arana Therapeutics Ltd. ,...
08:00 , Nov 14, 2011 |  BC Week In Review  |  Company News

Scancell, Teva deal

Scancell will receive a £2.9 million ($4.6 million) payment from Arana Therapeutics Ltd. (formerly Peptech Ltd. ) under a 2006 deal under which Scancell sold its portfolio of antibodies to Arana. The payment was triggered...
07:00 , Mar 15, 2010 |  BioCentury  |  Finance

Ebb & Flow

IB Australian Bioscience capitalized on a nice return from a 2008 fund to launch a new Asia-Pacific healthcare fund with a maximum fund size of A$200 million ($181.4 million). The venture fund will invest in...
08:00 , Feb 8, 2010 |  BioCentury  |  Strategy

Footprint for growth

Investors often worry that when companies add low-margin products to a high-margin portfolio, earnings will suffer. Cephalon Inc. Chairman and CEO Frank Baldino says the company's proposed acquisition of generics company Mepha AG should allow...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Company News

Progen management update

Progen Pharmaceuticals Ltd. (ASX:PGL; NASDAQ:PGLA), Brisbane, Australia   Business: Cancer   Hired: John Chiplin, a director, as interim CEO; formerly managing director at Arana Therapeutics Ltd. (now part of Cephalon Inc. )  ...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Company News

BioAssets, Cephalon deal

Cephalon will pay $30 million for an option to acquire BioAssets. The option will be exercisable up until 60 days following the receipt of one-month patient response data from a proof-of-concept Phase II trial of...
00:28 , Oct 27, 2009 |  BC Extra  |  Company News

Cephalon gains option to acquire BioAssets

Cephalon Inc. (NASDAQ:CEPH) will pay $30 million for an option to acquire BioAssets Development Corp. (Wellesley, Mass.). The option will be exercisable up until 60 days following the receipt of one-month patient response data from...
07:00 , Sep 14, 2009 |  BC Week In Review  |  Company News

Cephalon, Xoma Ltd. deal

Xoma and Cephalon's Arana Therapeutics Ltd. subsidiary will use Xoma's antibody technologies to develop antibodies for undisclosed indications. Arana will receive exclusive, worldwide rights to compounds developed under the deal. Xoma will receive $6 million...